AI-assisted 4D PET imaging to detect early pancreatic cancer lesions

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

Researchers will perform whole-body PET/CT scans using 18F-FDG and 68Ga-FAPI, along with four-dimensional dynamic long-axial imaging, to visualize early pancreatic lesions from metabolic, fibrotic, and receptor-expression perspectives. An AI tool will assist in detecting and characterizing lesions and distinguishing benign from malignant findings. Imaging results will be compared with postoperative histopathology to measure diagnostic performance. The study is observational and will enroll adults with suspected pancreatic tumors who have not yet received a histopathological diagnosis.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients with suspected pancreatic tumors larger than 1.0 cm.
* No histopathological diagnosis available before enrollment.
* No prior treatment for the suspected pancreatic tumor.
* Histopathological diagnosis obtained through surgery or biopsy within 2 months after PET imaging.
* Able and willing to provide written informed consent.
* Willing and able to comply with the study procedures and follow-up requirements.
* Male or female, aged 18-75 years.
* In generally good health, with an estimated life expectancy of more than 6 months and able to tolerate the imaging procedures.

Exclusion Criteria:

* Severe concomitant diseases that, in the investigator's judgment, make participation in the study inappropriate, including severe cardiopulmonary dysfunction or severe hepatic or renal impairment.
* Pregnancy, suspected pregnancy, or breastfeeding.
* Poor compliance with the study procedures.

Where it's running

• Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
  Shanghai, China Recruiting

Study contacts

• Study coordinator: Li
• Email: lb10363@rjh.com.cn
• Phone: 0086-021-64370045

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Zoldonrasib plus Daraxonrasib vs Gemcitabine and Nab-Paclitaxel as first-line treatment for metastatic KRAS G12D pancreatic cancer

  This study tests whether two investigational RAS inhibitors together can improve outcomes compared with standard chemotherapy in adults with newly diagnosed metastatic pancreatic cancer carrying the KRAS G12D mutation.

  Recruiting at 6 sites Phase 3 Revolution Medicines, Inc. · Phoenix, Arizona and 5 other locations · NCT07805954

• Biophotonic blood test to spot pancreatic cancer risk in at‑risk adults

  A blood test using light-based technology is being tested to see if it can predict pancreatic cancer development in people at risk, and also check how well treatments work for those affected.

  Recruiting Fondazione Policlinico Universitario Campus Bio-Medico · Rome, Italy · NCT07659639

• Zoldonrasib + chemotherapy vs placebo + chemotherapy as first-line treatment for metastatic KRAS G12D pancreatic cancer

  This trial tests whether adding zoldonrasib to standard chemotherapy helps people with newly diagnosed metastatic KRAS G12D pancreatic cancer.

  Recruiting at 25 sites Phase 3 Revolution Medicines, Inc. · Phoenix, Arizona and 24 other locations · NCT07621718

• Atebimetinib plus gemcitabine and nab‑paclitaxel as first‑line treatment for metastatic pancreatic cancer

  This trial will test whether adding the MAPK pathway drug atebimetinib to gemcitabine and nab‑paclitaxel helps people with newly diagnosed metastatic pancreatic ductal adenocarcinoma live longer.

  Recruiting at 76 sites Phase 3 Immuneering Corporation · Huntsville, Alabama and 75 other locations · NCT07562152

• Personalised Functional Profiling in colorectal cancer and pancreatic cancer

  This study tests a personalized drug-profiling approach using patient tumors to see if lab drug responses match actual patient outcomes in colorectal cancer and pancreatic cancer.

  Recruiting Luxembourg Institute of Health · Luxembourg, Luxembourg · NCT07500259

• Daraxonrasib alone or with gemcitabine and nab-paclitaxel for first-line metastatic pancreatic cancer

  This trial will see if daraxonrasib, alone or with gemcitabine and nab-paclitaxel, helps people with newly diagnosed metastatic pancreatic cancer live longer or slow tumor growth compared with standard gemcitabine and nab-paclitaxel.

  Recruiting at 61 sites Phase 3 Revolution Medicines, Inc. · Phoenix, Arizona and 81 other locations · NCT07491445

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.